Kiyoto Koibuchi

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM Erythropoiesis-stimulating agent (ESA) treatment during the predialysis period can be a strategy to reduce cardiac mortality soon after initiation of dialysis. In this study, we compared the(More)
  • 1